Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
640EU is a vaccine product referenced as a "Class II vaccine" with a dosage of "1.0 ml" per available documentation. It is associated with the Chinese vaccine industry and appears to be produced by one of the major private sector vaccine companies in China, which has expanded through acquisitions and infrastructure upgrades to meet GMP standards. The specific antigen, disease target, or mechanism of action for 640EU is not detailed in the available sources; however, it is classified as a Class II vaccine under Chinese regulatory definitions, which typically includes vaccines for diseases such as influenza, hepatitis A/B/E, varicella, mumps, rubella, and others that are not part of China's national immunization program but are still important for public health[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 640EU.